SLS draws attention on RVMD's pancreatic cancer drug approval; short-term focus on AML
RVMD Revolution Medicines Inc
$215.44 +1.92%
View chart & analysis → 
- 1Cellular (SLS) sees retail interest as FDA approves Revolution Medicines' (RVMD) RAS(ON) for advanced pancreatic cancer
- 2SLS009 has yet to enter human trials for pancreatic cancer; mid-stage data for newly diagnosed AML slated for Q4 this year
- 3Short-term focus is on AML; GPS REGAL has completed 78 of the 80 events needed as of May, with analysis pending
This 3-line summary is compiled from the report below.
Barrons.com +1 View original ↗
오늘의 AI 픽 5종목, 무료로 전부 공개합니다숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다